Key result
Extending the duration of oral anticoagulation beyond 4-6 weeks for venous thromboembolism requires weighing individual factors such as hemorrhage risk, recurrence, compliance, and cost.
Why the study?
What is the optimal duration of oral anticoagulant therapy in patients with venous thromboembolism?
What is the optimal duration of oral anticoagulant therapy in patients with venous thromboembolism?
Answers are grounded in this paper and cite their sources.
The optimal duration of oral anticoagulation for VTE often extends beyond 4-6 weeks and requires individualized decision-making balancing recurrence and bleeding risks.
Recent trials with sufficient statistical power have demonstrated that the duration of oral anticoagulation in many cases need to be extended well beyond 4-6 weeks. Since many individual factors, as risk of hemorrhage and of recurrence, compliance and cost have to be weighed into a decision, it is difficult to issue general recommendations. Several of these factors, especially those influencing the risk of recurrent event are reviewed here. The ideal solutions will perhaps only be achieved when we have learned how to combine the optimal duration with a time-adjusted decrease in oral anticoagulation.
No takes yet. Share an insight, caveat, or question.
Sam Schulman (1997) conducted a review in Venous Thromboembolism. Oral Anticoagulant Therapy was evaluated. Extending the duration of oral anticoagulation beyond 4-6 weeks for venous thromboembolism requires weighing individual factors such as hemorrhage risk, recurrence, compliance, and cost.
Synapse has enriched 10 related papers. Consider them for comparative context: